Literature DB >> 17573041

Peripheral nerve regeneration by the in vitro differentiated-human bone marrow stromal cells with Schwann cell property.

Satoshi Shimizu1, Masaaki Kitada, Hiroto Ishikawa, Yutaka Itokazu, Shohei Wakao, Mari Dezawa.   

Abstract

We examined the availability of human bone marrow stromal cells (MSCs) as a source of transplantation therapy in nerve injury. Human MSCs were subjected to a series of treatments with a reducing agent, retinoic acid and a combination of trophic factors. Morphologically and immunocytochemically, such treated cells differentiated into Schwann cell characteristics in vitro. Cells were filled into a transpermeable tube, transplanted into the gap made in the rat sciatic nerve of a rat and followed up to 3weeks under the control of immunosuppressant. In contrast to untreated human MSCs, differentiated human MSCs expressed Schwann cell markers in vivo and supported regenerating axons. These results suggest that human MSCs can be induced to be a substitute for Schwann cells that may be applied for nerve regeneration.

Entities:  

Mesh:

Year:  2007        PMID: 17573041     DOI: 10.1016/j.bbrc.2007.05.212

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  34 in total

Review 1.  Current state of the development of mesenchymal stem cells into clinically applicable Schwann cell transplants.

Authors:  Yu Pan; Sa Cai
Journal:  Mol Cell Biochem       Date:  2012-07-11       Impact factor: 3.396

2.  The isolation and cultivation of bone marrow stem cells and evaluation of differences for neural-like cells differentiation under the induction with neurotrophic factors.

Authors:  Jian-Dong Yang; Jing-Cheng Wang; Xin-Min Feng; Yi-Nan Li; Hai-Xiang Xiao
Journal:  Cytotechnology       Date:  2014-01-01       Impact factor: 2.058

Review 3.  Systematic neuronal and muscle induction systems in bone marrow stromal cells: the potential for tissue reconstruction in neurodegenerative and muscle degenerative diseases.

Authors:  Mari Dezawa
Journal:  Med Mol Morphol       Date:  2008-05-11       Impact factor: 2.309

Review 4.  Pluripotent stem cells for Schwann cell engineering.

Authors:  Ming-San Ma; Erik Boddeke; Sjef Copray
Journal:  Stem Cell Rev Rep       Date:  2015-04       Impact factor: 5.739

Review 5.  Augmenting peripheral nerve regeneration using stem cells: A review of current opinion.

Authors:  Neil G Fairbairn; Amanda M Meppelink; Joanna Ng-Glazier; Mark A Randolph; Jonathan M Winograd
Journal:  World J Stem Cells       Date:  2015-01-26       Impact factor: 5.326

6.  VEGF-A promotes both pro-angiogenic and neurotrophic capacities for nerve recovery after compressive neuropathy in rats.

Authors:  Julien Pelletier; Emilie Roudier; Pierre Abraham; Bérengère Fromy; Jean Louis Saumet; Olivier Birot; Dominique Sigaudo-Roussel
Journal:  Mol Neurobiol       Date:  2014-05-28       Impact factor: 5.590

7.  The secretome of MUSE cells contains factors that may play a role in regulation of stemness, apoptosis and immunomodulation.

Authors:  Nicola Alessio; Servet Özcan; Kazuki Tatsumi; Ayşegül Murat; Gianfranco Peluso; Mari Dezawa; Umberto Galderisi
Journal:  Cell Cycle       Date:  2016-07-27       Impact factor: 4.534

8.  Efficient generation of functional Schwann cells from adipose-derived stem cells in defined conditions.

Authors:  Songtao Xie; Fan Lu; Juntao Han; Ke Tao; Hongtao Wang; Alfred Simental; Dahai Hu; Hao Yang
Journal:  Cell Cycle       Date:  2017-03-15       Impact factor: 4.534

9.  Human umbilical vein-derived dopaminergic-like cell transplantation with nerve growth factor ameliorates motor dysfunction in a rat model of Parkinson's disease.

Authors:  Ming Li; Shi-Zhong Zhang; Yan-Wu Guo; Ying-qian Cai; Zhong-jie Yan; Zhihao Zou; Xiao-Dan Jiang; Yi-Quan Ke; Xu-ying He; Zeng-liang Jin; Guo-hui Lu; Dao-qing Su
Journal:  Neurochem Res       Date:  2010-07-24       Impact factor: 3.996

Review 10.  Advances in nerve repair.

Authors:  Helene T Khuong; Rajiv Midha
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.